Literature DB >> 12069837

Mitogenic action of LPA in prostate.

Yehia Daaka1.   

Abstract

The lipid growth factor lysophosphatidic acid (LPA) elicits multiple cellular responses, including cell growth and survival. LPA acts upon target cells by activating its cognate receptors, which belong to the G protein-coupled endothelial differentiation gene (EDG) family. To date, three known LPA receptors, termed LPA1, LPA2 and LPA3, have been molecularly characterized and cloned. Here, we review recent data describing the molecular steps involved in the LPA receptor-mediated activation of mitogenic extracellular signal-regulated kinase (ERK) pathway in prostate cancer. Induction of ERK by LPA proceeds via Gbetagamma-dependent activation of tyrosine kinases, including the epidermal growth factor (EGF) receptor and c-Src. Further, LPA-induced ERK activation involves matrix metalloproteinases (MMPs), which cause the release of active EGFR ligands. Finally, we present data demonstrating a correlation between the mitogenic effects of LPA and expression of the lp(A1) gene in the prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069837     DOI: 10.1016/s1388-1981(02)00180-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  25 in total

Review 1.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

Review 2.  High-fat diet, obesity and prostate disease: the ATX-LPA axis?

Authors:  Prakash Kulkarni; Robert H Getzenberg
Journal:  Nat Clin Pract Urol       Date:  2009-02-10

3.  Positive and Negative Cross-Talk between Lysophosphatidic Acid Receptor 1, Free Fatty Acid Receptor 4, and Epidermal Growth Factor Receptor in Human Prostate Cancer Cells.

Authors:  Mandi M Hopkins; Ze Liu; Kathryn E Meier
Journal:  J Pharmacol Exp Ther       Date:  2016-07-29       Impact factor: 4.030

4.  TRP channels in prostate cancer: the good, the bad and the ugly?

Authors:  Dimitra Gkika; Natalia Prevarskaya
Journal:  Asian J Androl       Date:  2011-05-30       Impact factor: 3.285

5.  Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.

Authors:  Y-M Chang; L Bai; S Liu; J C Yang; H-J Kung; C P Evans
Journal:  Oncogene       Date:  2008-08-04       Impact factor: 9.867

Review 6.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

7.  Lysophosphatidic Acid Upregulates Laminin-332 Expression during A431 Cell Colony Dispersal.

Authors:  Hironobu Yamashita; Manisha Tripathi; Jerome Jourquin; Yoonseok Kam; Shanshan Liu; Brandy Weidow; Vito Quaranta
Journal:  J Oncol       Date:  2010-08-25       Impact factor: 4.375

8.  Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity.

Authors:  Marion David; Irma Machuca-Gayet; Junichi Kikuta; Penelope Ottewell; Fuka Mima; Raphael Leblanc; Edith Bonnelye; Johnny Ribeiro; Ingunn Holen; Rùben Lopez Vales; Pierre Jurdic; Jerold Chun; Philippe Clézardin; Masaru Ishii; Olivier Peyruchaud
Journal:  J Biol Chem       Date:  2014-01-15       Impact factor: 5.157

9.  Lysophosphatidic acid signaling through LPA receptor subtype 1 induces colony scattering of gastrointestinal cancer cells.

Authors:  Kum-Joo Shin; You Lim Kim; Sukmook Lee; Dong-Kyu Kim; Curie Ahn; Junho Chung; Jae Young Seong; Jong-Ik Hwang
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-01       Impact factor: 4.553

10.  Csk mediates G-protein-coupled lysophosphatidic acid receptor-induced inhibition of membrane-bound guanylyl cyclase activity.

Authors:  K S Madhusoodanan; Dagang Guo; Deirdre K McGarrigle; Thomas Maack; Xin-Yun Huang
Journal:  Biochemistry       Date:  2006-03-14       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.